
eFigure. Patient 2: Immunostaining With CD25, FoxP3, and CD8 Antibodies

This supplementary material has been provided by the authors to give readers additional information about their work.
Immunostaining of patient N°2 with CD25 antibodies at baseline (A), at the end of the treatment (B), and at 2 months follow-up (C); with FOXP3 antibodies at baseline (D), at the end of the treatment (E), and at 2 months follow-up (F); and with CD8 antibodies at baseline (G), at the end of the treatment (H), and at 2 months follow-up (I).